Ask AI
ProCE Banner Activity

Optimizing Integration of Bispecific Antibody Therapy to Improve Clinical Outcomes in Patients With Multiple Myeloma

Slideset

Downloadable slides on optimizing the integration of bispecific antibody therapy in multiple myeloma, with a focus on emerging clinical data, patient selection, sequencing, and personalization of treatment. Toxicity management, step-up dosing, outpatient care, and multidisciplinary strategies for safe and effective implementation are also reviewed.

Released: August 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Johnson & Johnson

Target Audience

This activity is intended for hematologists, oncologists, emergency medicine physicians, neurologists, infectious disease specialists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with multiple myeloma who are eligible for or receiving bispecific antibody therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients and caregivers on the biologic rationale, mechanisms of action, administration, and treatment process for bispecific antibody therapy in R/R MM

  • Assess each patient’s eligibility and potential barriers to receiving bispecific antibodies that are approved or under investigation in R/R MM

  • Personalize treatment using approved or investigational bispecific antibodies for each eligible patient with R/R MM, considering available data, expert recommendations, and patient preferences

  • Implement effective workflow processes to monitor and manage bispecific antibody–related toxicities in patients with MM using the latest evidence and expert-recommended strategies

  • Develop plans for coordinating care among different specialists, departments, and/or centers to optimize each patient’s therapeutic benefit from bispecific antibody therapy for MM